



Alaninyl variants of the marine natural product halocyamine A and their antibacterial properties

Hugo K.H. Fong, Melissa Cadelis, Jean Michel Brunel, Marie-Lise Bourguet-Kondracki, David Barker, Brent Copp

► To cite this version:

Hugo K.H. Fong, Melissa Cadelis, Jean Michel Brunel, Marie-Lise Bourguet-Kondracki, David Barker, et al.. Alaninyl variants of the marine natural product halocyamine A and their antibacterial properties. *Tetrahedron*, 2018, 74 (48), pp.6929-6938. 10.1016/j.tet.2018.10.021 . hal-02056446

HAL Id: hal-02056446

<https://amu.hal.science/hal-02056446>

Submitted on 5 Mar 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Alaninyl variants of the marine natural product halocyamine A and their antibacterial properties

Hugo K. H. Fong^a, Melissa M. Cadelis^a, Jean Michel Brunel^b, Marie-Lise Bourguet-Kondracki^c, David Barker^a, Brent R. Copp^{a,*}

^a *School of Chemical Sciences, The University of Auckland, Private Bay 92019, Auckland 1142, New Zealand*

^b *UMR_MD1 “Membranes et Cibles Thérapeutiques”, U1261 INSERM, Aix-Marseille Université, Faculté de pharmacie, 27 Bd Jean Moulin, 13385, Marseille, cedex 5, France*

^c *Laboratoire Molécules de Communication et Adaptation des Micro-organismes, UMR 7245 CNRS, Muséum National d'Histoire Naturelle, 57 rue Cuvier (C.P. 54), 75005 Paris, France*

Keywords: Antibacterial; Halocyamine; Enamide; Marine natural product

* Corresponding author. E-mail address: b.copp@auckland.ac.nz (B.R. Copp).

Abstract

In an effort to explore the antibacterial potential of the marine natural product halocyamine A, a series of analogues including desbromo and alanine-substituted variants were synthesised and evaluated for biological activity against a panel of Gram-positive and –negative bacteria. The analogues were synthesised by a combination of solid-phase peptide synthesis and ruthenium complex/ytterbium triflate catalysed hydroamidation chemistry. Single alanine substitutions ([Ala¹]-halocyamine A and [Ala²]-halocyamine A) gave only modest increases in activity towards Gram-positive bacteria, while di-alaninyl variants exhibited more potent activity with MIC values of 12.5–50 μ M towards the Gram-positive bacteria *S. aureus* and *E. faecalis*. A lipophilic trityl-protected intermediate of [Ala²]-halocyamine was the most active against the Gram negative bacterium *Escherichia coli*.

1. Introduction

The tunichromes are small, modified peptides isolated from the blood cells of marine organisms belonging to the Class Ascidiacea.[ref1, ref2, ref3] Structurally, these natural products are typified by the presence of a C-terminal decarboxy- $\Delta^{2,3}$ -enamide fragment. While the C-terminus amino acid is usually tyrosine, 3,4-dihydroxyphenylalanine (DOPA) or 3,4,5-trihydroxyphenylalanine (TOPA)-derived, the halocyamines (e.g. A, **1**) are unusual in that the C-terminus moiety is derived from 6-bromo-tryptophan. A number of ecological roles have been proposed for the tunichromes, varying from tunic formation (cross-linking)[ref4], acting as a primitive wound repair system, to metal ion sequestration[ref5] or that they act as antimicrobial agents.[ref4] Indeed there is growing body of biochemical evidence that many of these roles are at least feasible.

As part of our ongoing investigation of the chemistry and biology of tunichromes, we have recently reported the synthesis and structural confirmation of the tunichromes Sp-1 [ref6] and halocyamine A (**1**).[ref7] With only modest levels of antibacterial activity being observed for synthetic halocyamine A, we sought to use our robust synthetic methodology to prepare novel halocyamine A analogues that explored the influence of bromine substitution and of the His and DOPA amino acids on the biological activity. Herein we report the synthesis and antibacterial activities of these halocyamine A analogues.




Fig 1. Structures of halocyamine A (**1**) and des-bromo analogue **2**

2. Results and discussion

In our previously reported synthesis of halocyamine A (**1**), the natural product was disconnected at the DOPA-Gly amide bond to give two fragments, Fmoc-His(Trt)-DOPA(TBS)₂-OH (**3**) and Z-enamide **4** (Fig. 2). [ref7] The two fragments were prepared separately using Fmoc solid phase peptide synthesis (SPPS) and ruthenium-catalysed hydroamidation of an indole-acetylene, respectively.





Fig 2. Fragments **3** – **5**.


In the current project, we sought to explore the influence, if any, of bromine substitution and each of the amino acids L-His and L-DOPA on the observed antibacterial activity of halocyamine A. To this end, our first target was des-bromo halocyamine A **2**, which required synthesis of indole-enamide **5**. The known indolic alkyne **6** [Ref8 Unsworth] was subjected to hydroamidation with Fmoc-glycinamide using 5 mol% bis(2-methylallyl)(1,5-cyclooctadiene)ruthenium(II) heated at 70 °C for 32 h to give glycy-Z-enamide **7** (69%) and by-product (*E*)-enyne **8**[ref7] (18%) (Scheme 1). Enamide **7** was then deprotected (TFA/CH₂Cl₂) to give **5** in 89% yield.



Scheme 1. *Reagents and conditions:* (i) Fmoc-glycinamide (0.5 eq.), bis(2-methylallyl)(1,5-cycloocta-diene)ruthenium(II) (0.025 eq.), 1,4-bis(dicyclohexylphosphino)butane (0.03 eq.), ytterbium triflate (0.02 eq.), DMF, H₂O, 70 °C, 32 h, 69% (**7**) and 18% (**8**); (ii) TFA (60 eq.), CH₂Cl₂, 0 °C, 8 h, 89%.


EDC-mediated coupling of enamide **5** and protected dipeptide Fmoc-His(Trt)-DOPA(TBDMS)₂-OH **3** [ref7] afforded the protected halocyamine analogue **9** in 39% yield (Scheme 2). Step-wise fmoc deprotection (piperidine, DMF, 20 min) to give **10** (68% yield), followed by desilylation (triethylamine trihydrofluoride, THF, 55 min) to give **11** (69% yield) and lastly, removal of the trityl

group (HCl/HFIP, H₂O, TIS, 1 h) afforded des-bromo halocytamine **A 2** as the dihydrochloride salt in 73% yield.




Scheme 2. *Reagents and conditions:* (i) EDC.HCl (1.5 eq.), HOBt (2 eq.), DIPEA (6 eq.), CH₂Cl₂, 9 h, 39%; (ii) piperidine, DMF, r.t. 20 min, 68%; (iii) Et₃N.3HF, THF, 0 °C, 55 min, 69%; (iv) 0.01 N HCl/HFIP, H₂O, TIS, r.t., 1 h, 73%.

We next explored the antibacterial influence of the L-histidine and/or L-DOPA residues of halocytamine **A** by preparing two L-alanine-substituted variants **12** and **13**. The first of these analogues (**12**), where Ala replaced His, required the protected dipeptide Fmoc-Ala-DOPA(TBDMS)₂-OH (**14**) which was prepared using standard Fmoc-SPPS methodology in 85% yield (see experimental). Bromo-indole enamide **4**[ref7] was then coupled (EDC, HOBt, DIPEA, 7.5 h) with **14** to give **15** in 42% yield (Scheme 3). Removal of the Fmoc protecting group (piperidine, DMF, 20 min) gave the chromatographically-separable (*Z*)-**16** (36%) and (*E*)-**16** (31%). Desilylation of (*Z*)-**16** (triethylamine trihydrofluoride, THF, 55 min) gave [Ala¹]-halocytamine **A 12** in 67% yield.



Scheme 3. *Reagents and conditions:* (i) **4** (1 eq.), EDC.HCl (1.5 eq.), HOBT (2 eq.), DIPEA (6 eq.), CH₂Cl₂, r.t., 7.5 h, 42%; (ii) piperidine, DMF, r.t., 20 min, 36% (*Z*), 31% (*E*); (iii) Et₃N.3HF, THF, 0 °C, 55 min, 67%.

A similar reaction sequence was used to prepare the second Ala-variant **13** with Ala replacing the DOPA residue. Dipeptide **17**, prepared by Fmoc-SPPS in 88% yield, was coupled with **4** to give **18** in 44% yield (Scheme 3). Deprotection at the N-terminus (piperidine, DMF, 20 min) gave **19** (86%) which followed by removal of the trityl group (HCl/HFIP, H₂O, TIS, 1 h) afforded [Ala²]-halocytamine A (**13**) (83%) as an inseparable mixture of *Z/E* (1:0.9) isomers.



Scheme 1. *Reagents and conditions:* (i) **4** (1 eq.), EDC.HCl (1.1 eq.), HOBT (1.5 eq.), DIPEA (5 eq.), CH₂Cl₂, DMF, r.t., 8 h, 44%; (ii) piperidine, DMF, r.t., 20 min, 86%; (iii) 0.01 N HCl/HFIP, H₂O, TIS, r.t., 1 h, 83% (*Z/E*, 1:0.9).

A final two analogues were prepared that explored substituting both His and DOPA residues for either L-Ala-L-Ala (**20**) or D-Ala-D-Ala (**21**). The requisite fmoc-dipeptides **22** and **23** were prepared by SPSS and then coupled with **4** (EDC, HOBT, DIPEA, 8h) to afford, respectively **24** (33%) or **25**

(34%). Subsequent deprotection (piperidine, DMF, 20 min) gave [Ala¹,Ala²]-halocytamine A **20** (60%) or [D-Ala¹,D-Ala²]-halocytamine A **21** (69%), respectively.





Fig. 3. Fmoc-protected dipeptides **22** and **23**.



Scheme 2. Reagents and conditions: (i) piperidine, DMF, r.t., 20 min, 60%; (ii) piperidine, DMF, r.t., 20 min, 69%.

Des-bromo halocytamine A **2**, alanine analogues **12** and **13**, di-alaninyl analogues **20** and **21** and a number of the reaction intermediates (**15**, **16**, **18**, **19**, **24**, **25**) were evaluated against a panel of Gram-negative (*Pseudomonas aeruginosa* ATCC 27853, *Escherichia coli* ATCC 25922) and Gram-positive (*Staphylococcus aureus* ATCC 25923, *Enterococcus faecalis* ATCC 29212) bacteria and for cytotoxicity towards the mammalian L6 rat skeletal myoblast cell line (Table 1). As we have previously noted, halocytamine A exhibits poor levels of antibacterial activity, with a modest MIC of 100 μ M towards *P. aeruginosa* and *E. faecalis*.^[ref7] In the present study, the des-bromo analogue **2** failed to exhibit any antibacterial activities, while both of the [Ala¹] (**12**) and [Ala²] (**13**) analogues (the latter tested as an *E/Z* mixture of isomers) showed a modest increase in activity towards Gram-positive bacteria (*S. aureus* MIC 100 μ M; *E. faecalis* 50 – 100 μ M). An interesting finding related to the [Ala²] analogue was the enhanced activity towards the Gram-negative bacterium *E. coli* (MIC

25–50 μM) for the fmoc/trityl (**19**) and trityl-protected (**19**) intermediates. Although these same two compounds also exhibited cytotoxicity towards the L6 cell line (IC_{50} 65.6 and 25.6 μM , respectively) the observation of antibacterial activity for these compounds and not for the corresponding de-tritylated analogue (**13**) suggests that the presence of a sterically bulky lipophilic residue at the His-residue position in halocyamine A may be a useful starting point for the discovery of novel Gram-negative antibacterials.

Gram-positive antibacterial activity was observed for both di-alaninyl analogues with the di-L-alaninyl variant **20** exhibiting activity towards *S. aureus* (MIC 12.5 μM) and the di-D-alaninyl analogue **21** exhibiting activity towards both *S. aureus* and *E. faecalis* (both MIC 50 μM). Modest cytotoxicity was observed for these analogues (IC_{50} 115.8 and 142 μM , respectively), equating to a selectivity index (= cytotoxicity IC_{50} / antibacterial MIC) in the case of di-L-alaninyl **20** of close to ten. The antibacterial activity for both di-alaninyl analogues was dependent upon a free amine at the *N*-terminus, as both fmoc-protected precursors (**24** and **25**) were inactive.

Table 1Summary of biological activities observed for compounds **1, 2, 12, 13, 15, 16, 18-21, 24** and **25**.

Compound	<i>P. aeruginosa</i> ^a	<i>E. coli</i> ^b	<i>S. aureus</i> ^c	<i>E. faecalis</i> ^d	L6 ^e
1 HaloA	100	>200	>200	100	NT ^f
2 HF7-137 Des	>200	>200	>200	NT	>150
12 HF7-154 Ala¹	>200	>200	100	50	82.8
13 HF8-141 Ala^{2 g}	>200	>200	100	100	136.8
15 HF7-81 fmoc tbs ala-dopa	>200	>200	>200	NT	NT
16 HF7-140 tbs ala-dopa	>200	>200	25	NT	4.8
18 HF8-99/HF8-87 fmoc-trt-his-ala	>200	50	>200	>200	65.6
19 HF8-102 trt-his-ala	>200	25	25	200	25.6
20 HF8-100/HF8-103 Ala-Ala	>200	200	12.5	200	115.8
21 HF8-136 d-ala-d-ala	>200	>200	50	50	142
24 HF8-81 fmoc Ala-Ala	>200	100	200	>200	48.5
25 HF8-118/HF8-95 fmoc-d-ala-d-ala	>200	>200	100	100	NT

Colistin	1	2			
Chloramphenicol			1.5 – 3	1.5 – 3	
Podophyllotoxin					0.013

^a *P. aeruginosa* ATCC27853. MIC (μM) values presented as the mean (n = 3).

^b *E. coli* ATCC25922. MIC (μM) values presented as the mean (n = 3).

^c *S. aureus* ATCC25923. MIC (μM) values presented as the mean (n = 3).

^d *E. faecalis* ATCC29212. MIC (μM) values presented as the mean (n = 3).

^e L6 rat skeletal myoblast cell line. IC₅₀ (μM) values presented as the average (n = 2).

^f Not tested.

^g Tested as a mixture of *E/Z* isomers.

3. Conclusions

In conclusion, we have established that alaninyl analogues of the marine natural product halocyamine A exhibit more pronounced antibacterial activities than the natural product. While single alanine substitutions gave modest increases in activity (to MIC 50–100 μ M), di-alaninyl analogues exhibited MIC values of 12.5–50 μ M towards the Gram-positive bacteria *S. aureus* and *E. faecalis*. The finding of activity of a His(Trt)-Ala analogue of halocyamine A towards *E. coli* is particularly encouraging, suggesting that exploration of increasingly lipophilic analogues of [Ala²]-halocyamine could be worthwhile in the search for new molecules active against Gram-negative bacteria.

4. Experimental

4.1. General

Infrared spectra were run as dry films on an FTIR infrared spectrometer fitted with a universal ATR sampling accessory. Optical rotations were recorded using a 0.1 dm cell in methanol. NMR spectra were recorded at either 500 or 400 MHz for ¹H nuclei and 125 or 100 MHz for ¹³C nuclei. Proto-deutero solvent signals were used as internal references (CD₃OD: δ_{H} 3.31, δ_{C} 49.0; CDCl₃: δ_{H} TMS 0, δ_{C} 77.16; DMSO-*d*₆: δ_{H} 2.50, δ_{C} 39.52). ¹H NMR data is reported as position (δ), relative integral, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, br = broad, obs = obscured), coupling constant (*J*, Hz), and the assignment of the atom. ¹³C NMR data are reported as position (δ) and assignment of the atom. Assignments were based on 2D NMR data acquired using standard COSY, multiplicity edited HSQC and HMBC pulse sequences. MS data were acquired on a micrOTOF Q II mass spectrometer. Flash column chromatography was carried out on C₂ or C₈ (reversed-phase) or on silica gel (normal phase). All solvents used were distilled analytical grade or better. Chemical reagents used were purchased from standard chemical suppliers. Compounds Fmoc-DOPA(TBDMS)₂-OH [Ref9 Sever tet 2001], Fmoc-His(Trt)-DOPA(TBDMS)₂-OH **3 HF2.19** [ref7], bromo-indole-enamide **4 HF3.1** [ref7] and indolic alkyne **6 HF3.10** [ref8 Unsworth 2013], were prepared by published routes and data obtained were in agreement with those previously reported.

4.1.1. *tert*-Butyl (Z)-3-(2-(2-aminoacetamido)vinyl)-1*H*-indole-1-carboxylate (**7 HF4-68**) and di-*tert*-butyl 3,3'-(but-1-en-3-yne-1,4-diyl)(*E*)-bis(1*H*-indole-1-carboxylate) (**8 HF8-14**)

Fmoc-Gly-NH₂ (0.296 g, 1.00 mmol), *tert*-butyl 3-ethynyl-1*H*-indole-carboxylate (0.482 g, 2.00 mmol), bis(2-methylallyl)(1,5-cycloocta-diene)ruthenium(II) (0.016 g, 0.05 mmol), 1,4-bis(dicyclohexylphosphino)butane (0.027 g, 0.06 mmol) and ytterbium triflate (0.025 g, 0.04 mmol) were placed under vacuum and then flushed with N₂ (four times). A degassed DMF (3.00 mL) / water

(108 μ L, 6 mmol) mixture was added and the solution stirred under N₂ at 70 °C for 32 h. The reaction was then quenched with sat. aq. NaHCO₃ (30 mL) and the resulting mixture extracted with EtOAc (5 x 20 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried (MgSO₄), filtered, and the solvent removed in vacuo. Purification using silica gel column chromatography (eluting with n-hexane to n-hexane/EtOAc 9:1) afforded **8 HF8-14** (0.087 g, 18%) as a brown oil while elution with a more polar solvent mixture (n-hexane/EtOAc 1:1 to EtOAc) gave **7 HF4-68** (0.220 g, 69%) as a yellow oil.

4.1.1.1. 7 HF4-68: R_f 0.15 (n-hexane/EtOAc 8:2); IR (ATR) ν_{\max} 3329, 2973, 2931, 1700, 1451, 1368, 1253, 1149 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 9.71 (1H, d, *J* = 11.6 Hz, H-4), 8.13 (1H, d, *J* = 7.9 Hz, H-10), 7.76 (1H, s, H-8), 7.58 (1H, d, *J* = 7.9 Hz, H-13), 7.36 (1H, td, *J* = 7.9, 1.2 Hz, H-11), 7.28 (1H, td, *J* = 7.9, 1.2 Hz, H-12), 7.06 (1H, dd, *J* = 11.6, 9.2 Hz, H-5), 5.86 (1H, d, *J* = 9.2 Hz, H-6), 3.47 (2H, s, H₂-2), 1.68 (9H, s, CO₂C(CH₃)₃); ¹³C NMR (CDCl₃, 100 MHz) δ 170.5 (C-3), 149.7 (CO₂C(CH₃)₃), 135.1 (C-9a), 129.9 (C-13a), 125.2 (C-11), 123.0 (C-12), 122.6 (C-8), 121.9 (C-5), 119.4 (C-13), 115.9 (C-7), 115.3 (C-10), 100.4 (C-6), 84.0 (CO₂C(CH₃)₃), 44.6 (C-2), 28.3 (CO₂C(CH₃)₃); (+)-HRESIMS [M+H]⁺ 316.1650 (calcd. for C₁₇H₂₂N₃O₃, 316.1656).

4.1.1.2. 8 HF8-14: R_f 0.79 (n-hexane/EtOAc 4:1); IR (ATR) ν_{\max} 2977, 2933, 2865, 1733, 1451, 1368, 1231, 1147, 1093 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 8.18–8.14 (2H, m, H-7 and H-15), 7.78 (1H, s, H-13), 7.78–7.73 (2H, m, H-4 and H-18), 7.70 (1H, s, H-2), 7.37–7.32 (2H, m, H-6 and H-16), 7.31–7.26 (2H, m, H-5 and H-17), 7.17 (1H, d, *J* = 15.8 Hz, H-8), 6.52 (1H, d, *J* = 15.8 Hz, H-9), 1.66–1.65 (18H, m, 3H₃-21 and 3H₃-24); ¹³C NMR (CDCl₃, 100 MHz) δ 149.4 (C-19 or C-22), 149.1 (C-19 or C-22), 136.1 (C-7a), 134.8 (C-14a), 132.6 (C-8), 130.6 (C-18a), 128.5 (C-13), 128.2 (C-3a), 125.2 (C-6 or C-16), 125.0 (C-6 or C-16), 124.8 (C-2), 123.29 (C-5 or C-17), 123.27 (C-5 or C-17), 120.2 (C-4 or C-18), 120.0 (C-4 or C-18), 118.5 (C-3), 115.6 (C-7 or C-15), 115.3 (C-7 or C-15), 108.0 (C-9), 103.9 (C-12), 92.9 (C-10), 84.24 (C-20 or C-23), 84.17 (C-20 or C-23), 83.4 (C-11), 28.19 (3C-21 or 3C-24), 28.17 (3C-21 or 3C-24); (+)-HRESIMS [M+Na]⁺ 505.2091 (calcd. for C₃₀H₃₀N₂O₄Na, 505.2098).

4.1.2. (Z)-N-(2-(1H-Indol-3-yl)vinyl)-2-aminoacetamide (5 HF4-154)

A solution of **7 HF4-68** (0.17 g, 0.436 mmol) in CH₂Cl₂ (2 mL) was stirred at 0 °C under N₂ for 5 min before TFA (2 mL, 26.1 mmol) was added dropwise. The solution was then stirred for a further 8 h at 0 °C. The reaction was quenched with sat. aq. NaHCO₃ (20 mL) and extracted with EtOAc (4 x 20 mL). The organic layers were combined and dried in vacuo. The crude black oil was purified by silica gel column chromatography (eluting with EtOAc to CH₂Cl₂/MeOH 9:1) to afford **5**

HF4-154 (0.13 g, 89%) as a black oil. R_f 0.50 (CH₂Cl₂/MeOH 9:1); IR (ATR) ν_{\max} 3403, 3295, 1655, 1535, 1499, 1231 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 9.53 (1H, br s, NH-4), 8.30 (1H, br s, NH-9), 7.65 (1H, d, J = 7.5 Hz, H-13), 7.40 (1H, d, J = 8.6 Hz, H-10), 7.35 (1H, d, J = 2.4 Hz, H-8), 7.27–7.24 (1H, m, H-11), 7.18 (1H, t, J = 7.5 Hz, H-12), 6.98 (1H, dd, J = 11.5, 9.2 Hz, H-5), 6.00 (1H, d, J = 9.2 Hz, H-6), 3.45 (2H, s, H₂-2); ¹³C NMR (CDCl₃, 100 MHz) δ 170.3 (C-3), 135.9 (C-9a), 126.8 (C-13a), 123.0 (C-11), 121.8 (C-8), 120.3 (C-12), 119.7 (C-13), 119.5 (C-5), 112.0 (C-7), 111.3 (C-10), 102.6 (C-6), 44.7 (C-2); (+)-HRESIMS [M+H]⁺ 216.1130 (calcd. for C₁₂H₁₄N₃O, 216.1131).

4.1.3. (9*H*-Fluoren-9-yl)methyl ((*S*)-1-(((*S*)-1-((2-(((*Z*)-2-(1*H*-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-3-(3,4-bis((*tert*-butyldimethylsilyl)oxy)phenyl)-1-oxopropan-2-yl)amino)-1-oxo-3-(1-*trityl*-1*H*-imidazol-4-yl)propan-2-yl)carbamate (**10 HF7-118**)

To a solution of dipeptide **3 HF2.19** (0.43 g, 0.42 mmol), enamide **5 HF4-154** (0.09 g, 0.42 mmol), EDC.HCl (0.12 g, 0.63 mmol) and HOBt (0.11 g, 0.84 mmol) in CH₂Cl₂ (3 mL) was added DIPEA (0.44 mL, 2.5 mmol) under N₂ and stirred for 9 h. The reaction mixture was diluted with CH₂Cl₂ (15 mL), washed with water (10 mL) and the organic solvent removed *in vacuo*. Subsequent purification by silica gel column chromatography (eluting with *n*-hexane/EtOAc 9:1 to *n*-hexane/EtOAc 1:1) afforded **9 HF7-118** (0.20 g, 39%) as a yellow oil. $[\alpha]^{26.7}_D +16.6$ (*c* 1.57, CH₂Cl₂); R_f 0.58 (CH₂Cl₂/MeOH 9:1); IR (ATR) ν_{\max} 2930, 2861, 1714, 1670, 1509, 1447, 1297, 1253, 1155, 1130 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 9.02 (2H, br s, NH-20 and NH-28), 8.22 (1H, d, J = 10.9 Hz, NH-23), 7.75 (2H, d, J = 6.8 Hz, H-FmocAr), 7.73 (1H, d, J = 7.3 Hz, H-FmocAr), 7.56 (1H, d, J = 7.7 Hz, H-32), 7.52–7.49 (1H, m, 2H-FmocAr), 7.39–7.36 (4H, m, H-6, H-29 and 2H-FmocAr), 7.30–7.25 (7H, m, H-FmocAr and 6H-TrtAr), 7.24–7.20 (3H, m, H-27, H-30 and H-FmocAr), 7.07–7.05 (3H, m, H-31 and 3H-TrtAr), 7.00–6.99 (6H, m, 6H-TrtAr), 6.74–6.73 (2H, m, H-17 and H-24), 6.68 (2H, br s, NH-10 and H-14), 6.56–6.54 (2H, m, H-8 and H-18), 6.01 (1H, d, J = 5.9 Hz, NH-1), 5.88 (1H, d, J = 9.1 Hz, H-25), 4.76 (1H, br s, H-11), 4.31–4.29 (3H, m, CO₂CH₂CH and H-2), 4.15–4.12 (2H, m, CO₂CH₂CH and H₂-21a), 3.76 (1H, dd, J = 16.7, 4.8 Hz, H₂-21b), 3.07 (1H, dd, J = 14.2, 7.1 Hz, H₂-12a), 3.00–2.94 (2H, m, H₂-3a and H₂-12b), 2.65 (1H, br s, H₂-3b), 0.97–0.95 (18H, m, 2Si(CH₃)₃), 0.17–0.16 (12H, m, 2Si(CH₃)₂); ¹³C NMR (CDCl₃, 125 MHz) δ 172.1 (C-19), 170.6 (C-9), 166.6 (C-22), 156.2 (CO₂CH₂CH), 147.3 (C-15), 146.3 (C-16), 143.9 (C-FmocAr), 143.7 (C-FmocAr), 141.4 (2C-FmocAr and 3C-TrtAr), 135.9 (C-28a), 129.8 (3C-TrtAr), 129.7 (6C-TrtAr), 129.2 (C-13), 128.4 (6C-TrtAr), 127.9 (2C-FmocAr), 127.2 (2C-FmocAr), 127.1 (C-32a), 125.2 (2C-FmocAr), 122.9 (C-27), 122.7 (C-30), 122.3 (C-18), 122.0 (C-14), 121.3 (C-17), 120.9 (C-8), 120.2 (2C-FmocAr), 120.0 (C-31), 119.0 (C-32), 118.9 (C-24), 111.5 (C-29), 111.1 (C-26), 103.4 (C-25), 67.4 (CO₂CH₂CH), 54.7 (C-2 and C-11), 47.2 (CO₂CH₂CH), 43.9 (C-21), 36.6 (C-12), 29.5 (C-3),

26.1 (2SiC(CH₃)₃), 18.6 (2SiC(CH₃)₃), -3.9 (2Si(CH₃)₂); (+)-HRESIMS [M+H]⁺ 1224.5848 (calcd. for C₇₃H₈₂N₇O₇Si₂, 1224.5809).

4.1.4. (*S*)-*N*-(2-(((*Z*)-2-(1*H*-Indol-3-yl)vinyl)amino)-2-oxoethyl)-2-((*S*)-2-amino-3-(1-trityl-1*H*-imidazol-4-yl)propanamido)-3-(3,4-bis((*tert*-butyldimethylsilyl)oxy)phenyl)propanamide (**10 HF7-88**)

Piperidine (0.18 mL, 1:4 v/v in DMF) was added to **9 HF7-118** (43.9 mg, 35.9 μmol) and stirred at r.t. under N₂ for 20 min. Water (10 mL) was added to the solution and the aqueous layer was extracted with EtOAc (4 x 20 mL). The organic layers were combined and dried in vacuo. The crude product was purified by silica gel column chromatography (eluting with EtOAc to CH₂Cl₂/MeOH 9:1) to afford **10 HF7-88** (24.5 mg, 68%) as a yellow oil. [α]^{26.7}_D -12.2 (c 2.66, CH₂Cl₂); R_f 0.62 (CH₂Cl₂/MeOH 9:1); IR (ATR) ν_{max} 2931, 2857, 1659, 1509, 1445, 1364, 1251, 1230, 1158, 1132, 1092 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ 9.40 (1H, br s, NH-28), 8.72 (1H, dd, *J* = 6.0, 6.0 Hz, NH-20), 8.24 (1H, d, *J* = 10.9 Hz, NH-23), 7.57 (1H, d, *J* = 7.8 Hz, H-32), 7.36–7.34 (2H, m, H-6 and H-29), 7.31–7.26 (6H, m, 6H-TrtAr), 7.25–7.23 (1H, m, H-27), 7.21–7.17 (1H, m, H-30), 7.13–7.06 (4H, m, H-31, and 3H-TrtAr), 7.02–7.00 (6H, m, 6H-TrtAr), 6.89 (1H, d, *J* = 7.8 Hz, NH-10), 6.74–6.70 (2H, m, H-17 and H-24), 6.68–6.67 (1H, m, H-14), 6.58–6.55 (2H, m, H-8 and H-18), 5.87 (1H, d, *J* = 9.1 Hz, H-25), 4.69 (1H, ddd, *J* = 7.8, 7.2, 6.4 Hz, H-11), 4.12 (1H, dd, *J* = 16.8, 6.0 Hz, H₂-21a), 3.83 (1H, dd, *J* = 16.8, 6.0 Hz, H₂-21b), 3.50 (1H, dd, *J* = 5.2, 5.2 Hz, H-2), 3.05 (1H, dd, *J* = 14.1, 7.2 Hz, H₂-12a), 2.99 (1H, dd, *J* = 14.1, 7.2 Hz, H₂-12b), 2.85 (1H, dd, *J* = 14.7, 5.2 Hz, H₂-3a), 2.71 (1H, dd, *J* = 14.7, 5.2 Hz, H₂-3b), 0.97–0.96 (18H, m, 2SiC(CH₃)₃), 0.17–0.16 (12H, m, 2Si(CH₃)₂); ¹³C NMR (CDCl₃, 100 MHz) δ 174.9 (C-9), 172.3 (C-19), 166.7 (C-22), 147.1 (C-15), 146.1 (C-16), 142.2 (3C-TrtAr), 128.1 (3C-TrtAr), 139.0 (C-6), 136.0 (C-4), 135.8 (C-28a), 129.8 (C-13), 129.7 (6C-TrtAr), 128.3 (6C-TrtAr), 127.1 (C-32a), 123.1 (C-27), 122.6 (C-30), 122.3 (C-18), 122.1 (C-14), 121.3 (C-17), 120.6 (C-8), 119.9 (C-31), 118.9 (C-32), 118.6 (C-24), 111.4 (C-29), 110.8 (C-26), 103.6 (C-25), 75.6 (CAr₃), 54.40 (C-2 or C-11), 54.37 (C-2 or C-11), 43.8 (C-21), 36.6 (C-12), 33.1 (C-3), 26.1 (2SiC(CH₃)₃), 18.6 (SiC(CH₃)₃), 18.5 (SiC(CH₃)₃), -3.9 (2Si(CH₃)₂); (+)-HRESIMS [M+H]⁺ 1002.5152 (calcd. for C₅₈H₇₂N₇O₅Si₂, 1002.5128).

4.1.5. (*S*)-*N*-(2-(((*Z*)-2-(1*H*-Indol-3-yl)vinyl)amino)-2-oxoethyl)-2-((*S*)-2-amino-3-(1-trityl-1*H*-imidazol-4-yl)propanamido)-3-(3,4-dihydroxy phenyl)propanamide (**11 HF8-25**)

Triethylamine trihydrofluoride (4.59 μL, 28.5 μmol) was added to a solution of **10 HF7-88** (9.5 mg, 9.5 μmol) in THF (0.50 mL) at 0 °C and stirred under N₂ for 55 min. The reaction mixture was dried under a stream of N₂ and water (15 mL) was added. The aqueous layer was extracted with CH₂Cl₂ (4 x 20 mL) and the organic layers were combined and solvent was removed *in vacuo* to give

a yellow oil. Purification by silica gel column chromatography (eluting with EtOAc to MeOH/CH₂Cl₂, 1:9), afforded **11 HF8-25** (5.1 mg, 69%) as a yellow oil. $[\alpha]^{22.2}_D -5.1$ (*c* 0.28, CH₂Cl₂); *R_f* 0.33 (CH₂Cl₂/MeOH 9:1); IR (ATR) ν_{\max} 3312, 1657, 1493, 1445, 1281, 1155, 1037 cm⁻¹; ¹H NMR (CD₃OD, 500 MHz) δ 7.52, (1H, d, *J* = 7.9 Hz, H-32), 7.41 (1H, br s, H-27), 7.36 (1H, d, *J* = 1.4 Hz, H-6), 7.34–7.31 (10H, m, H-29 and 9H-TrtAr), 7.12–7.09 (1H, m, H-30), 7.09–7.07 (6H, m, 6H-TrtAr), 7.04–7.01 (1H, m, H-31), 6.68 (1H, br s, H-8), 6.64–6.61 (3H, m, H-14, H-17 and H-24), 6.49 (1H, dd, *J* = 8.1, 2.1 Hz, H-18), 5.99 (1H, d, *J* = 9.0 Hz, H-25), 4.54 (1H, dd, *J* = 9.1, 5.3 Hz, H-11), 3.88 (2H, br s, H₂-21), 3.53 (1H, dd, *J* = 5.8, 5.6 Hz, H-2), 3.01 (1H, dd, *J* = 14.1, 5.3 Hz, H₂-12a), 2.80 (1H, dd, *J* = 14.7, 5.6 Hz, H₂-3a), 2.74–2.67 (2H, m, H₂-3b and H₂-12b); ¹³C NMR (CD₃OD, 125 MHz) δ 175.7 (C-9), 174.6 (C-19), 169.2 (C-22), 146.3 (C-15), 145.3 (C-16), 143.6 (3C-TrtAr), 139.8 (C-6), 137.51 (C-4 or C-28a), 137.48 (C-4 or C-28a), 130.8 (6C-TrtAr), 129.7 (C-13), 129.2 (9C-TrtAr), 128.2 (C-32a), 124.7 (C-27), 123.1 (C-30), 121.7 (C-8 or C-18)*, 121.6 (C-8 or C-18)*, 120.5 (C-31), 119.4 (C-32), 118.8 (C-24), 117.3 (C-14), 116.3 (C-17), 112.4 (C-29), 111.0 (C-26), 106.2 (C-25), 76.8 (C-Ar₃), 56.3 (C-11), 55.4 (C-2), 44.1 (C-21), 37.9 (C-12), 33.8 (C-3); (+)-HRESIMS [M+Na]⁺ 774.3411 (calcd. for C₄₆H₄₇N₄O₆Na, 774.3388).

4.1.6. Des-bromo halocyanine A dihydrochloride (**2 HF7-137**)

A cocktail solution of 0.01 N HCl/HFIP-TIS/H₂O (2 mL, 95:2.5:2.5) was added to **11 HF8-25** (48.6 mg, 0.0628 mmol) and stirred for 1 h. The reaction was dried under a stream of N₂. Purification by C₈ column chromatography (eluting with H₂O to H₂O/MeOH 6:4) afforded **2 HF7-137** (24.4 mg, 73%) as a white powder. m.p. 260 °C (decomposed); *R_f* 0.87 (butan-1-ol/acetic acid/H₂O 2:1:1); $[\alpha]^{23.0}_D +7.8$ (*c* 0.43, MeOH); IR (ATR) ν_{\max} 3262, 3024, 2928, 1652, 1494, 1445, 1258, 1184, 1079, 1032 cm⁻¹; ¹H NMR (DMSO-*d*₆, 500 MHz) δ 11.39 (1H, s, NH-28), 9.06 (1H, d, *J* = 10.1 Hz, NH-23), 8.71 (1H, d, *J* = 18.7 Hz, NH-20), 8.13 (1H, d, *J* = 6.0 Hz, NH-10), 7.71 (1H, d, *J* = 2.0 Hz, H-27), 7.60 (1H, d, *J* = 8.0 Hz, H-32), 7.55 (1H, s, H-6), 7.39 (1H, d, *J* = 8.0 Hz, H-29), 7.12 (1H, t, *J* = 8.0 Hz, H-30), 7.04 (1H, t, *J* = 8.0 Hz, H-31), 6.82 (1H, br s, H-8), 6.65 (1H, dd, *J* = 10.1, 9.6 Hz, H-24), 6.61–6.58 (2H, m, H-14 and H-17), 6.42 (1H, dd, *J* = 8.0, 1.8 Hz, H-18), 5.95 (1H, d, *J* = 9.6 Hz, H-25), 4.44 (1H, br s, H-11), 3.99 (1H, dd, *J* = 18.7, 5.9 Hz, H₂-21a), 3.93 (1H, dd, *J* = 18.7, 5.9 Hz, H₂-21b), 3.38 (1H, obs, H-2), 2.92 (1H, dd, *J* = 13.9, 4.2 Hz, H₂-12a), 2.80 (1H, dd, *J* = 14.5, 4.4 Hz, H₂-3a), 2.68 (1H, dd, *J* = 13.9, 9.0 Hz, H₂-12b), 2.53 (1H, d, *J* = 8.7 Hz, H₂-3b); ¹³C NMR (DMSO-*d*₆, 125 MHz) δ 172.0 (C-19), 167.5 (C-22), 144.8 (C-15), 143.7 (C-16), 135.5 (C-28a), 134.9 (C-6), 128.4 (C-13), 126.6 (C-32a), 123.9 (C-27), 121.6 (C-30), 120.0 (C-18), 119.0 (C-31), 118.2 (C-32), 117.8 (C-24), 116.6 (C-14), 115.2 (C-17), 111.5 (C-29), 109.4 (C-26), 102.8 (C-25), 54.9 (C-2), 53.9 (C-11), 42.6 (C-21), 39.8 (C-3), 36.9 (C-12); (+)-HRESIMS [M+H]⁺ 532.2296 (calcd. for C₂₇H₃₀N₇O₅, 532.2303).

4.1.7. Fmoc-Ala-DOPA(TBDMS)₂-OH (**14 HF7-60**)

A solution of Fmoc-DOPA(TBDMS)₂-OH [Ref9 Sever Tet 2001] (0.65 g, 1.0 mmol) in CH₂Cl₂ (15 mL) was added to 2-chlorotrityl chloride resin (2 g, loading at 0.5 mmol/g), followed by DIPEA (0.17 mL, 1.0 mmol). After the resin mixture was agitated for 10 min, DIPEA (0.26 mL, 1.5 mmol) was added and the mixture was further shaken for 1 h. The solution was drained off and the resin was washed with DMF (10 mL). A solution of CH₂Cl₂/MeOH/DIPEA (12.5 mL, 80:15:5) was added to the mixture and shaken for 23 min. The solution was drained and the procedure was repeated. The resin was then washed with DMF (10 mL). Piperidine in DMF (12.5 mL, 1:4) was added to the resin mixture and shaken for 10 min. The liquid was drained off and piperidine washing was repeated for another 20 min. The amino acid-loaded resin was thoroughly washed with DMF (15 mL), isopropanol (15 mL) and *n*-hexane (15 mL). The resin was then dried under vacuum for 30 min and placed in a desiccator overnight. CH₂Cl₂ (30 mL) was added to the resin and left for 1 h. The solution was drained and a solution of HBTU (1.42 g, 3.75 mmol), HOBt (0.570 g, 3.75 mmol), Fmoc-Ala-OH (0.62 g, 2.0 mmol) and DIPEA (0.87 mL, 5.0 mmol) in DMF (3.75 mL) was added. The amino acid resin mixture was agitated for 5 h. The solution was then drained and washed with DMF (20 mL), isopropanol (20 mL) and *n*-hexane (20 mL). 2,2,2-Trifluoroethanol in CH₂Cl₂ (12.5 mL, 1:4) was added to the amino acid-loaded resin and agitated for 2 h. The solution was drained and the organic solvent was removed *in vacuo* and dried extensively to afford **14 HF7-60** (0.61 g, 85%) as a yellow foam. m.p. 79–80 °C; $[\alpha]^{25.1}_{\text{D}} +10.2$ (*c* 1.59, CH₂Cl₂); *R_f* 0.38 (EtOAc); IR (ATR) ν_{max} 2932, 2858, 1719, 1665, 1509, 1450, 1423, 1297, 1251, 1127 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 7.74 (2H, d, *J* = 7.3 Hz, 2H-FmocAr), 7.57 (2H, d, *J* = 7.3 Hz, 2H-FmocAr), 7.38 (2H, t, *J* = 7.3 Hz, 2H-FmocAr), 7.28 (2H, t, *J* = 7.3 Hz, 2H-FmocAr), 6.70 (1H, d, *J* = 8.2 Hz, H-12), 6.65 (1H, d, *J* = 1.9 Hz, H-9), 6.59–6.57 (1H, m, H-13), 6.53 (1H, br s, NH-5), 5.56 (1H, br s, NH-1), 4.75 (1H, ddd, *J* = 6.2, 6.2, 6.2 Hz, H-6), 4.38–4.36 (2H, m, CO₂CH₂CH), 4.23 (1H, br s, H-2), 4.19 (1H, t, *J* = 7.0 Hz, CO₂CH₂CH), 3.07 (1H, dd, *J* = 14.0, 6.2 Hz, H₂-7a), 2.98 (1H, dd, *J* = 14.0, 6.2 Hz, H₂-7b), 1.32 (3H, d, *J* = 5.7 Hz, H₃-3), 0.95–0.94 (18H, m, 2SiC(CH₃)₃), 0.16–0.14 (12H, m, 2Si(CH₃)₂); ¹³C NMR (CDCl₃, 125 MHz) δ 174.6 (C-14), 172.5 (C-4), 156.1 (CO₂CH₂CH), 147.0 (C-10), 146.3 (C-11), 143.8 (2C-FmocAr), 141.4 (2C-FmocAr), 128.7 (C-8), 127.9 (2C-FmocAr), 127.2 (2C-FmocAr), 125.2 (2C-FmocAr), 122.4 (C-13), 122.1 (C-9), 121.2 (C-12), 120.1 (2C-FmocAr), 67.3 (CO₂CH₂CH), 53.5 (C-6), 50.6 (C-2), 47.2 (CO₂CH₂CH), 36.8 (C-7), 26.0 (2SiC(CH₃)₃), 18.9 (C-3), 18.5 (2SiC(CH₃)₃), -3.9 (2Si(CH₃)₂); (+)-HRESIMS [M+Na]⁺ 741.3381 (calcd. for C₃₉H₅₄NaN₂O₇Si₂, 741.3362).

4.1.8. (9H-Fluoren-9-yl)methyl ((S)-1-(((S)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)-1-((2-(((Z)-2-(6-bromo-1H-indol-3-yl)vinyl)amino)-2-oxoethyl) amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl) carbamate (**15 HF7-81**)

To a solution of enamide **4 HF3.1** (0.14 g, 0.49 mmol), **14 HF7-60** (0.36 g, 0.49 mmol), EDC.HCl (0.14 g, 0.73 mmol) and HOBt (0.13 g, 0.98 mmol) in CH₂Cl₂ (5 mL) under N₂, was added DIPEA (0.51 mL, 2.9 mmol) and the solution was stirred at r.t. for 7.5 h. Water (10 mL) was added and the crude reaction product was extracted with EtOAc (4 x 15 mL). The organic layers were combined, dried (MgSO₄), filtered and solvent removed *in vacuo* to give a crude oil. Purification by silica gel column chromatography (eluting with *n*-hexane/EtOAc 9:1 to *n*-hexane/EtOAc 1:1) afforded **15 HF7-81** (112 mg, 42%) as a yellow oil. *R*_f 0.45 (*n*-hexane/EtOAc 1:1); [α]^{24.8}_D +3.2 (*c* 0.52, CH₂Cl₂); IR (ATR) ν_{\max} 3280, 2931, 2858, 1629, 1504, 1447, 1293, 1252, 1160 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 9.15 (1H, br s, NH-23), 8.36 (1H, d, *J* = 10.2 Hz, NH-18), 7.74 (2H, d, *J* = 7.2 Hz, 2H-FmocAr), 7.52 (2H, t, *J* = 7.2 Hz, 2H-FmocAr), 7.44 (1H, d, *J* = 1.2 Hz, H-24), 7.39–7.36 (3H, m, H-27 and 2H-FmocAr), 7.27 (2H, t, *J* = 7.2 Hz, 2H-FmocAr), 7.21 (1H, d, *J* = 1.9 Hz, H-22), 7.18 (1H, dd, *J* = 8.5, 1.2 Hz, H-26), 7.14 (1H, br s, NH-15), 6.94 (1H, d, *J* = 7.5 Hz, NH-5), 6.80 (1H, dd, *J* = 10.2, 9.6 Hz, H-19), 6.68 (1H, d, *J* = 8.2 Hz, H-12), 6.63 (1H, d, *J* = 2.0 Hz, H-9), 6.51 (1H, dd, *J* = 8.2, 2.0 Hz, H-13), 5.87 (1H, d, *J* = 9.6 Hz, H-20), 5.36 (1H, d, *J* = 4.2 Hz, NH-1), 4.62 (1H, ddd, *J* = 7.5, 7.5, 7.5 Hz, H-6), 4.37 (2H, d, *J* = 6.1 Hz, CO₂CH₂CH), 4.15–4.10 (1H, m, CO₂CH₂CH), 4.09–4.03 (2H, m, H-2 and H₂-16a), 3.82–3.78 (1H, m, H₂-16a), 2.96 (1H, dd, *J* = 13.9, 7.5 Hz, H₂-7a), 2.86 (1H, dd, *J* = 13.9, 7.5 Hz, H₂-7b), 1.17 (3H, d, *J* = 7.0 Hz, H₃-3), 0.95–0.93 (18H, m, 2SiC(CH₃)₃), 0.14–0.13 (12H, m, 2Si(CH₃)₂); ¹³C NMR (CDCl₃, 125 MHz) δ 172.6 (C-4), 172.3 (C-14), 166.6 (C-17), 156.7 (CO₂CH₂CH), 147.1 (C-10), 146.3 (C-11), 143.7 (C-FmocAr), 143.6 (C-FmocAr), 141.42 (C-FmocAr), 141.41 (C-FmocAr), 136.7 (C-23a), 129.2 (C-8), 128.0 (2C-FmocAr), 127.3 (2C-FmocAr), 125.9 (C-27a), 125.0 (2C-FmocAr), 123.5 (C-22), 123.2 (C-26), 122.1 (C-9 or C-13), 122.0 (C-9 or C-13), 121.2 (C-12), 120.2 (C-27 and 2C-FmocAr), 119.5 (C-19), 116.2 (C-25), 114.4 (C-24), 110.9 (C-21), 103.4 (C-20), 67.3 (CO₂CH₂CH), 54.6 (C-6), 51.3 (C-2), 47.2 (CO₂CH₂CH), 44.0 (C-16), 37.4 (C-7), 26.0 (2SiC(CH₃)₃), 18.6 (SiC(CH₃)₃), 18.5 (SiC(CH₃)₃), 18.2 (C-3), –4.0 (2Si(CH₃)₂); (+)-HRESIMS [M+Na]⁺ 1016.3451 (calcd. for C₅₁H₆₄Na⁷⁹BrN₅O₇Si₂, 1016.3420).

4.1.9. (S)-2-((S)-2-Aminopropanamido)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)-N-(2-((2-(6-bromo-1H-indol-3-yl)vinyl)amino)-2-oxoethyl)propanamide (**16 HF7-140**)

Piperidine (0.23 mL, 20% in DMF) was added to **15 HF7-81** (47.0 mg, 0.0473 mmol) and the solution was stirred under N₂ at r.t. for 20 min. EtOAc (15 mL) was added and the mixture was washed with water (5 mL). The aqueous layer was further washed with EtOAc (3 x 15 mL) and then

the organic layers were combined and dried *in vacuo*. The crude product was purified by silica gel column chromatography (eluting with EtOAc to CH₂Cl₂/MeOH 9:1), to afford **Z-16 HF7-140Z** (13.0 mg, 36%) and **E-16 HF7-140E** (13.0 mg, 31%) as yellow oils.

4.1.9.1. Z-16 HF7-140Z: *R_f* 0.71 (CH₂Cl₂/MeOH 9:1); [α]^{22.3}_D +22.1 (*c* 1.14, CH₂Cl₂); IR (ATR) ν_{max} 3280, 2931, 1632, 1508, 1472, 1422, 1295, 1252, 1161, 1127 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 9.20 (1H, br s, NH-23), 8.29 (1H, d, *J* = 10.4 Hz, NH-18), 7.78 (1H, d, *J* = 7.8 Hz, NH-5), 7.53 (1H, br s, H-24), 7.43 (1H, d, *J* = 8.1 Hz, H-27), 7.23 (2H, br s, H-22 and H-26), 7.01 (1H, br s, NH-15), 6.83 (1H, dd, *J* = 10.4, 9.6 Hz, H-19), 6.73 (1H, d, *J* = 7.9 Hz, H-12), 6.66 (1H, s, H-9), 6.56 (1H, d, *J* = 7.9 Hz, H-13), 5.91 (1H, d, *J* = 9.6 Hz, H-20), 4.60–4.57 (1H, m, H-6), 4.04 (1H, dd, *J* = 16.7, 4.8 Hz, H₂-16a), 3.81 (1H, d, *J* = 16.7 Hz, H₂-16b), 3.38–3.37 (1H, m, H-2), 2.98 (1H, dd, *J* = 13.6, 5.9 Hz, H₂-7a), 2.88–2.84 (1H, m, H₂-7b), 1.16 (3H, d, *J* = 6.4 Hz, H₃-3), 0.97 (18H, br s, 2SiC(CH₃)₃), 0.16 (12H, br s, 2Si(CH₃)₂); ¹³C NMR (CDCl₃, 125 MHz) δ 176.5 (C-4), 172.6 (C-14), 166.5 (C-17), 147.1 (C-10), 146.3 (C-11), 136.7 (C-23a), 129.2 (C-8), 125.9 (C-27a), 123.4 (C-22 or C-26), 123.3 (C-22 or C-26), 122.22 (C-9 or C-13), 122.17 (C-9 or C-13), 121.3 (C-12), 120.3 (C-27), 119.7 (C-19), 116.4 (C-25), 114.4 (C-24), 111.1 (C-21), 103.3 (C-20), 54.3 (C-6), 50.7 (C-2), 43.9 (C-16), 37.3 (C-7), 26.1 (2SiC(CH₃)₃), 21.4 (C-3), 18.62 (2SiC(CH₃)₃), 18.55 (2SiC(CH₃)₃), –3.9 (2Si(CH₃)₂); (+)-HRESIMS [M+Na]⁺ 794.2745 (calcd. for C₃₆H₅₄⁷⁹BrNaN₅O₅Si₂, 794.2739).

4.1.9.2. E-16 HF7-140E: *R_f* 0.61 (CH₂Cl₂/MeOH 9:1); [α]^{22.6}_D +16.8 (*c* 0.83, CH₂Cl₂); IR (ATR) ν_{max} 3021, 2881, 1597, 1487, 1480, 1429, 1357, 1268, 1179, 1090 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 8.90 (1H, br d, *J* = 10.2 Hz, NH-18), 8.46 (1H, br s, NH-23), 7.93 (1H, br s, NH-5), 7.55 (1H, d, *J* = 8.5 Hz, H-27), 7.48 (1H, s, H-24), 7.32 (1H, dd, *J* = 14.7, 10.2 Hz, H-19), 7.18 (1H, dd, *J* = 8.5, 1.0 Hz, H-26), 7.10 (1H, s, H-22), 6.84 (1H, br s, NH-15), 6.77 (1H, d, *J* = 8.1 Hz, H-12), 6.70 (1H, d, *J* = 1.9 Hz, H-9), 6.65 (1H, dd, *J* = 8.1, 1.9 Hz, H-13), 6.48 (1H, d, *J* = 14.7 Hz, H-20), 4.30 (1H, ddd, *J* = 7.1, 7.1, 7.1 Hz, H-6), 4.13 (1H, dd, *J* = 16.9, 5.9 Hz, H₂-16a), 3.79 (1H, dd, *J* = 16.9, 5.9 Hz, H₂-16b), 3.51–3.48 (1H, m, H-2), 3.11 (1H, dd, *J* = 13.9, 7.1 Hz, H₂-7a), 2.93 (1H, dd, *J* = 13.9, 7.1 Hz, H₂-7b), 1.27 (3H, d, *J* = 7.0 Hz, H₃-3), 0.98–0.96 (18H, m, 2SiC(CH₃)₃), 0.18–0.17 (12H, m, 2Si(CH₃)₂); ¹³C NMR (CDCl₃, 125 MHz) δ 177.3 (C-4), 172.0 (C-14), 166.3 (C-17), 147.2 (C-10), 146.3 (C-11), 137.5 (C-23a), 129.2 (C-8), 124.6 (C-27a), 123.4 (C-26), 122.6 (C-22), 122.1 (C-9 or C-13)*, 122.0 (C-9 or C-13)*, 121.4 (C-12), 121.0 (C-27), 120.4 (C-19), 116.0 (C-25), 114.4 (C-24), 113.4 (C-21), 107.0 (C-20), 56.3 (C-6), 50.7 (C-2), 43.3 (C-16), 36.5 (C-7), 26.1 (2SiC(CH₃)₃), 21.2 (C-3), 18.63 (SiC(CH₃)₃), 18.57 (SiC(CH₃)₃), –3.9 (2Si(CH₃)₂); (+)-HRESIMS [M+Na]⁺ 794.2731 (calcd. for C₃₆H₅₅⁷⁹BrNaN₅O₅Si₂, 794.2739).

4.1.10. (S)-1-(((S)-1-((2-(((Z)-2-(6-Bromo-1H-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-3-(3,4-dihydroxy phenyl)-1-oxopropan-2-yl)amino)-1-oxopropan-2-aminium 2,2,2-trifluoroacetate (**12 HF7-154**)

A solution of **Z-16 HF7-140Z** (18.2 mg, 0.0236 mmol) in THF (2 mL) was stirred at 0 °C under N₂ for 10 min before triethylamine trihydrofluoride (14.0 µL, 0.0856 mmol) was added dropwise. The solution was stirred for 55 min and then dried under a stream of N₂. Purification using C₂ column chromatography [eluting with H₂O/MeOH/TFA (99.99:0:0.01 to 59.99:39.99:0.02)] afforded **12 HF7-154** (10.4 mg, 67%) as a yellow oil. R_f 0.87 (butan-1-ol/acetic acid/H₂O 2:1:1); [α]^{22.4}_D +5.9 (c 0.66, MeOH); IR (ATR) ν_{max} 3253, 2923, 1668, 1532, 1456, 1200, 1129, 1023 cm⁻¹; ¹H NMR (DMSO-*d*₆, 500 MHz) δ 11.46 (1H, s, NH-23), 9.22 (1H, d, *J* = 10.2 Hz, NH-18), 8.53 (1H, d, *J* = 8.5 Hz, NH-5), 8.39 (1H, dd, *J* = 5.7, 5.7 Hz, NH-15), 8.00–7.99 (3H, m, NH₃-1), 7.74 (1H, d, *J* = 2.4 Hz, H-22), 7.58 (1H, d, *J* = 1.7 Hz, H-24), 7.56 (1H, d, *J* = 8.4 Hz, H-27), 7.17 (1H, dd, *J* = 8.4, 1.7 Hz, H-26), 6.69–6.67 (2H, m, H-9 and H-19), 6.61 (1H, d, *J* = 8.1 Hz, H-12), 6.52 (1H, dd, *J* = 8.1, 2.0 Hz, H-13), 5.91 (1H, d, *J* = 9.5 Hz, H-20), 4.51 (1H, ddd, *J* = 4.4, 8.5, 9.6 Hz, H-6), 3.99 (1H, dd, *J* = 16.9, 5.7 Hz, H₂-16a), 3.93 (1H, dd, *J* = 16.9, 5.7 Hz, H₂-16b), 3.78–3.76 (1H, m, H-2), 2.89 (1H, dd, *J* = 13.9, 4.4 Hz, H₂-7a), 2.62 (1H, dd, *J* = 13.9, 9.6 Hz, H₂-7b), 1.32 (3H, d, *J* = 7.0 Hz, H₃-3); ¹³C NMR (DMSO-*d*₆, 125 MHz) δ 171.4 (C-14), 169.4 (C-4), 167.5 (C-17), 144.9 (C-10), 143.8 (C-11), 136.4 (C-23a), 128.4 (C-8), 125.7 (C-27a), 124.9 (C-22), 121.9 (C-26), 120.2 (C-27), 120.0 (C-13), 118.7 (C-19), 116.6 (C-9), 115.3 (C-12), 114.3 (C-25), 114.0 (C-24), 109.8 (C-21), 102.1 (C-20), 54.7 (C-6), 48.0 (C-2), 42.2 (C-16), 37.0 (C-7), 17.2 (C-3); (+)-HRESIMS [M+H]⁺ 544.1173 (calcd. for C₂₄H₂₇⁷⁹BrN₅O₅, 544.1190).

4.1.11. Fmoc-His(Trt)-Ala-OH (**17 HF8-62**)

A solution of Fmoc-L-Ala-OH (0.93 g, 3.0 mmol) in CH₂Cl₂ (25 mL) and DMF (2 mL) was added to 2-chlorotriptyl chloride resin (6 g, loading at 0.5 mmol/g), followed by DIPEA (0.52 mL, 3.0 mmol). After the resin mixture was agitated for 10 min, DIPEA (0.78 mL, 4.5 mmol) was added and the mixture was further shaken for 2 h. The solution was drained off and the resin was washed with DMF (30 mL). A solution of CH₂Cl₂/MeOH/DIPEA (20 mL, 80:15:5) was added to the mixture and shaken for 30 min. The solution was drained and the procedure was repeated. The resin was then washed with DMF (20 mL). Piperidine in DMF (15 mL, 1:4) was added to the resin mixture and shaken for 5 min. The liquid was drained off and piperidine washing was repeated for another 20 min. The amino acid-loaded resin was thoroughly washed with DMF (30 mL), isopropanol (30 mL) and *n*-hexane (30 mL). The resin was then dried under vacuum overnight. CH₂Cl₂ (40 mL) was added to the resin and left for 30 min. The solution was drained and a solution of HBTU (4.27 g, 11.25 mmol), HOBT (1.72 g, 11.25 mmol), Fmoc-His(Trt)-OH (4.65 g, 7.5 mmol) and DIPEA (2.61 mL, 15.0 mmol)

in DMF (11.3 mL) was added to the resin. The amino acid resin mixture was agitated for 5 h. The solution was then drained and washed with DMF (30 mL), isopropanol (30 mL) and *n*-hexane (30 mL). 2,2,2-Trifluoroethanol in CH₂Cl₂ (25 mL, 1:4) was added to the amino acid-loaded resin and agitated for 1.5 h. The solution was drained and the organic solvent removed *in vacuo* to afford **17 HF8-62** (1.82 g, 88%) as a yellow foam. m.p. 144.1–145.0 °C; *R_f* 0.55 (CH₂Cl₂/MeOH 9:1); [α]^{20.4}_D +10.7 (*c* 1.01, CH₂Cl₂); IR (ATR) ν_{\max} 3318, 3063, 1720, 1652, 1526, 1493, 1447, 1237, 1044 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 8.53 (1H, br s, NH-10), 7.76 (2H, d, *J* = 7.4 Hz, 2H-FmocAr), 7.56 (1H, s, H-8), 7.53 (1H, d, *J* = 7.8 Hz, H-FmocAr), 7.51 (1H, d, *J* = 7.8 Hz, H-FmocAr), 7.39 (1H, t, *J* = 7.4 Hz, 2H-FmocAr), 7.29–7.25 (11H, m, 2H-FmocAr, 9H-TrtAr), 7.04–7.02 (6H, m, 6H-TrtAr), 6.67 (1H, s, H-8), 5.88 (1H, br s, NH-1), 4.88 (1H, t, *J* = 10.7 Hz, H-2), 4.47 (1H, dq, *J* = 6.6, 6.6 Hz, H-11), 4.38 (1H, dd, *J* = 9.4, 7.3 Hz, CO₂CH₂CH), 4.07 (1H, t, *J* = 7.3 Hz, CO₂CH₂CH), 3.98 (1H, dd, *J* = 9.4 Hz, CO₂CH₂CH), 3.39 (1H, d, *J* = 13.2 Hz, H-3a), 2.58 (1H, dd, *J* = 13.2, 10.7 Hz, H-3b), 1.54 (1H, d, *J* = 6.6 Hz, H-12); ¹³C NMR (CDCl₃, 125 MHz) δ 176.8 (C-13), 171.0 (C-9), 156.0 (CO₂CH₂CH), 144.2 (C-FmocAr), 143.9 (C-FmocAr), 141.6 (3C-TrtAr), 141.4 (2C-FmocAr), 137.8 (C-6), 135.0 (C-4), 129.8 (6C-TrtAr), 128.6 (3C-TrtAr), 128.4 (6C-TrtAr), 127.8 (2C-FmocAr), 127.3 (2C-FmocAr), 125.6 (C-FmocAr), 125.3 (C-FmocAr), 120.4 (C-8), 120.1 (2C-FmocAr), 76.3 (CAr₃), 67.1 (CO₂CH₂CH), 54.9 (C-2), 50.0 (C-11), 47.3 (CO₂CH₂CH), 32.8 (C-3), 19.2 (C-12); (+)-HRESIMS [M+H]⁺ 691.2900 (calcd. for C₄₃H₃₉N₄O₅, 691.2915).

4.1.12. Fmoc-Trt-[Ala²]-halocycamine A (**18 HF8-87**)

Fmoc-L-His(Trt)-L-Ala-OH **17 HF8-62** (0.243 g, 0.352 mmol), EDC.HCl (0.074 g, 0.387 mmol) and HOBt (0.071 g, 0.527 mmol) were dissolved in CH₂Cl₂ (1.5 mL) and stirred for 1 h at r.t. under N₂. A solution of enamide **4 HF3.1** (0.103 g, 0.352 mmol) in DMF (0.5 mL) was added to the mixture followed by DIPEA (0.31 mL, 1.76 mmol). The solution was stirred at r.t. under N₂ for 7 h. The solution was diluted with EtOAc (10 mL) and washed with water (5 mL). The organic layer was dried (MgSO₄), filtered and the solvent removed *in vacuo*. The crude product was purified by silica gel flash column chromatography (eluting with *n*-hexane/EtOAc 8:2 to *n*-hexane/EtOAc/MeOH 5:4.5:0.5) to afford **18 HF8-87** (0.151 g, 44%) as a yellow oil. *R_f* 0.36 (EtOAc); [α]^{20.4}_D +15.3 (*c* 1.26, CH₂Cl₂); IR (ATR) ν_{\max} 3303, 2160, 1653, 1494, 1448, 1230, 1041, 1002 cm⁻¹; ¹H NMR (CHCl₃, 300 MHz) δ 9.34 (1H, s, NH-22), 9.13 (1H, dd, *J* = 6.1, 5.6 Hz, NH-15), 8.23 (1H, d, *J* = 10.8 Hz, NH-17), 7.73–7.71 (2H, m, 2H-FmocAr), 7.52 (1H, d, *J* = 8.2 Hz, H-FmocAr), 7.49 (1H, d, *J* = 8.2 Hz, H-FmocAr), 7.47 (1H, s, H-23), 7.40–7.36 (3H, m, 2H-FmocAr and H-26), 7.34 (1H, s, H-6), 7.29–7.26 (9H, m, 9H-TrtAr), 7.25–7.24 (3H, m, 2H-FmocAr and H-21), 7.21–7.17 (1 H, m, H-25), 7.03–7.02 (6H, m, 6H-TrtAr), 6.76–6.69 (2H, m, NH-10 and H-18), 6.61 (1H, s, H-8), 6.08 (1H, d, *J* = 6.3 Hz, NH-1), 5.80 (1H, d, *J* = 9.2 Hz, H-19), 4.55–4.51 (1H, m, H-11), 4.36–4.33 (3H,

m, CO₂CH₂CH and H-2), 4.15 (1H, t, *J* = 6.3 Hz, CO₂CH₂CH), 4.04 (1H, dd, *J* = 16.5, 6.1 Hz, H₂-15a), 3.87 (1 H, dd, *J* = 16.5, 5.6 Hz, H₂-15b), 3.00–2.84 (2 H, m, H₂-3), 1.31 (3 H, d, *J* = 7.3 Hz, H₃-12); ¹³C NMR (CDCl₃, 75 MHz) δ 173.5 (C-13), 171.1 (C-9), 167.0 (C-16), 156.4 (CO₂CH₂CH), 143.8 (2 x C-FmocAr), 142.1 (3 x C-TrtAr), 141.4 (2 x C-FmocAr), 138.9 (C-6), 136.6 (C-22a), 135.5 (C-4), 129.7 (6 x C-TrtAr), 128.4 (3 x C-TrtAr), 128.3 (6 x TrtAr), 128.0 (2 x C-FmocAr), 127.2 (2 x C-FmocAr), 125.9 (C-26a), 125.1 (2 x C-FmocAr), 123.6 (C-21), 123.2 (C-25), 120.6 (C-8), 120.3 (C-26), 120.2 (2 x C-FmocAr), 119.4 (C-18), 116.1 (C-24), 114.4 (C-23), 111.0 (C-20), 103.0 (C-19), 75.7 (CAr₃), 67.3 (CO₂CH₂CH), 55.0 (C-2), 49.3 (C-11), 47.2 (CO₂CH₂CH), 43.9 (C-15), 31.0 (C-3), 17.8 (C-12); (+)-HRESIMS [M+Na]⁺ 966.2957 (calcd. for C₅₅H₄₉⁷⁹BrNaN₇O₅, 966.2973).

4.1.13. Trt-[Ala²]-halocyclamine A (**19 HF8-102**)

A flask containing **18 HF8-87** (95.0 mg, 98.4 μmol) was flushed with N₂ before piperidine (20% in DMF, 1 mL) was added. The solution was stirred at r.t. for 20 min before EtOAc (20 mL) was added and the mixture was washed with water (10 mL). The aqueous layer was further washed with EtOAc (3 × 10 mL) and the organic layers were combined and dried *in vacuo*. Purification by silica gel column chromatography (eluting with EtOAc to CH₂Cl₂/MeOH 9:1), afforded **19 HF8-102** (62.8 mg, 86%) as a yellow oil. *R*_f 0.17 (CH₂Cl₂/MeOH 9:1); [α]^{20.7}_D -10.1 (*c* 0.24, CH₂Cl₂); IR (ATR) ν_{max} 3276, 1652, 1533, 1492, 1445, 1231, 1130, 1039 cm⁻¹; ¹H NMR (CHCl₃, 300 MHz) δ 9.80 (1H, s, NH-22), 8.76 (1H, dd, *J* = 5.8, 5.6 Hz, NH-14), 8.27 (1H, d, *J* = 10.2 Hz, NH-17), 7.48 (1H, d, *J* = 1.5 Hz, H-23), 7.38 (2H, d, *J* = Hz, H-6 and H-26), 7.32–7.28 (11H, m, NH-10, H-21 and 9H-TrtAr), 7.17 (1H, dd, *J* = 8.4, 1.5 Hz, H-25), 7.06–7.03 (6H, m, 6H-TrtAr), 6.74 (1H, dd, *J* = 10.2, 9.8 Hz, H-18), 6.64 (1H, s, H-8), 5.81 (1H, d, *J* = 9.8 Hz, H-19), 4.48–4.43 (1H, m, H-11), 4.05 (1H, dd, *J* = 16.9, 5.8 Hz, H₂-15a), 3.93 (1H, dd, *J* = 16.9, 5.6 Hz, H₂-15b), 3.66 (1H, s, H-2), 2.94 (1H, dd, *J* = 14.6, 4.8 Hz, H₂-3a), 2.84 (1H, dd, *J* = 14.6, 5.5 Hz, H₂-3b), 1.32 (3H, d, *J* = 7.2 Hz, H₃-12); ¹³C NMR (CDCl₃, 75 MHz) δ 174.7 (C-9), 173.6 (C-13), 167.1 (C-16), 142.0 (3C-TrtAr), 139.0 (C-6), 136.7 (C-4), 136.2 (C-22a), 129.7 (6C-TrtAr), 128.3 (6C-TrtAr), 128.2 (3C-TrtAr), 126.0 (C-26a), 123.8 (C-21), 123.1 (C-25), 120.5 (C-8), 120.2 (C-26), 119.3 (C-18), 116.0 (C-24), 114.4 (C-23), 110.8 (C-20), 103.2 (C-19), 75.7 (CAr₃), 54.6 (C-2), 49.4 (C-11), 43.8 (C-15), 33.1 (C-3), 17.8 (C-12); (+)-HRESIMS [M+H]⁺ 744.2307 (calcd. for C₄₄H₃₉⁷⁹BrN₇O₃, 744.2292).

4.1.14. [Ala²]-halocyclamine A (**13 HF8-141**)

A cocktail solution of 0.01 N HCl/HFIP-TIS/H₂O (1 mL, 95:2.5:2.5) was added to **19 HF8-102** (62.8 mg, 0.0844 mmol) and stirred for 1 h. The reaction was dried under a stream of N₂. Subsequent purification by C₈ column chromatography (eluting with H₂O to H₂O/MeOH 25:75) afforded **13 HF8-141** as an inseparable 1Z:0.9E mixture (yellow oil) (39.9 mg, 83%).

The mixture had the following properties: R_f 0.59 (butan-1-ol/acetic acid/H₂O 2:1:1); $[\alpha]^{21.6}_D$ -0.6 (c 1.03, MeOH); IR (ATR) ν_{\max} 3240, 2963, 1646, 1533, 1410, 1259, 1004 cm⁻¹; (+)-HRESIMS $[M+H]^+$ 502.1195 (calcd. for C₂₁H₂₅⁷⁹BrN₇O₃, 502.1197). NMR assignments for each of the isomers were discerned from 2D NMR data.

4.1.14.1. Z-13 HF8-141Z: ¹H NMR (CHCl₃, 300 MHz) δ 11.54 (1H, s, NH-22), 9.06 (1H, d, J = 9.9 Hz, NH-17), 8.80 (1H, br, s, NH-14), 8.20 (1H, d, J = 4.4 Hz, NH-10), 7.71 (1H, s, H-21), 7.59–7.54 (3H, m, H-6, H-23 and H-26), 7.20–7.14 (1H, m, H-25), 6.86–6.85 (1H, m, H-8), 6.67 (1H, dd, J = 9.9, 9.7 Hz, H-18), 5.92 (1H, d, J = 9.7 Hz, H-19), 4.33–4.31 (1H, m, H-11), 3.97–3.94 (2H, m, H₂-15), 3.48–3.40 (1H, m, H-2), 2.92–2.83 (1H, m, H₂-3a), 2.77–2.62 (1H, m, H₂-3b), 1.24 (3H, d, J = 7.1 Hz, H₃-12); ¹³C NMR (CDCl₃, 75 MHz) δ 174.1 (C-9), 173.1 (C-13), 167.6 (C-16), 136.4 (C-22a), 135.0 (C-6), 125.7 (C-26a), 124.8 (C-21), 122.1 (C-25), 120.6 (C-26), 118.6 (C-18), 114.3 (C-24), 114.0 (C-23), 109.7 (C-20), 102.3 (C-19), 54.7 (C-2), 48.1 (C-11), 42.5 (C-15), 32.7 (C-3), 18.2 (C-12);

4.1.14.2. E-13 HF8-141E: ¹H NMR (CHCl₃, 300 MHz) δ 11.26 (1H, s, NH-22), 9.71 (1H, d, J = 10.0 Hz, NH-17), 9.07–9.04 (1H, m, NH-14), 8.39 (1H, br, s, NH-10), 7.59–7.54 (3H, m, H-6, H-23 and H-26), 7.47 (1H, d, J = 2.0 Hz, H-21), 7.30 (1H, dd, J = 14.9, 10.0 Hz, H-18), 7.20–7.14 (1H, m, H-25), 6.86–6.85 (1H, m, H-8), 6.49 (1H, d, J = 14.9 Hz, H-19), 4.22–4.15 (1H, m, H-11), 3.86–3.84 (2H, m, H₂-15), 3.48–3.40 (1H, m, H-2), 2.92–2.83 (1H, m, H₂-3a), 2.77–2.62 (1H, m, H₂-3b), 1.28 (3H, d, J = 7.0 Hz, H₃-12); ¹³C NMR (CDCl₃, 75 MHz) δ 175.3 (C-9), 172.8 (C-13), 166.5 (C-16), 137.6 (C-22a), 134.9 (C-6), 124.3 (C-26a), 123.9 (C-21), 121.9 (C-25), 120.1 (C-26), 120.0 (C-18), 114.3 (C-24), 114.1 (C-23), 111.9 (C-20), 105.7 (C-19), 54.7 (C-2), 49.1 (C-11), 42.2 (C-15), 32.5 (C-3), 17.6 (C-12)

4.1.15. Fmoc-L-Ala-L-Ala-OH (**22 HF8-58**)

A solution of Fmoc-Ala-OH (0.93 g, 3.0 mmol) in CH₂Cl₂ (25 mL) was added to 2-chlorotriptyl chloride resin (6 g, loading at 0.5 mmol/g), followed by DIPEA (0.52 mL, 3.0 mmol). After the resin mixture was agitated for 14 min, DIPEA (0.78 mL, 4.5 mmol) was added and the mixture was further shaken for 2.5 h. The solution was drained off and the resin was washed with DMF (20 mL). A solution of CH₂Cl₂/MeOH/DIPEA (40 mL, 80:15:5) was added to the mixture and shaken for 30 min. The solution was drained and the procedure was repeated. The resin was then washed with DMF (20 mL). Piperidine in DMF (15.0 mL, 1:4) was added to the resin mixture and shaken for 10 min. The liquid was drained off and piperidine washing was repeated for another 40 min. The amino acid-loaded resin was thoroughly washed with DMF (35 mL), isopropanol (35 mL) and *n*-hexane (35 mL). The resin was then dried under vacuum for 30 min and placed in a desiccator overnight. CH₂Cl₂ (50 mL) was added to the resin and left for 1 h. The solution was drained and a solution of HBTU (4.27

g, 11.25 mmol), HOBt (1.72 g, 11.25 mmol), Fmoc-Ala-OH (2.34 g, 7.5 mmol) and DIPEA (2.61 mL, 15.0 mmol) in DMF (11.3 mL) was added. The amino acid resin mixture was agitated for 4 h. The solution was then drained and washed with DMF (30 mL), isopropanol (30 mL) and *n*-hexane (30 mL). 2,2,2-Trifluoroethanol in CH₂Cl₂ (15 mL, 1:4) was added to the amino acid-loaded resin and agitated for 2 h. The solution was drained and the organic solvent removed *in vacuo* to afford **22 HF8-58** (0.90 g, 78%) as a yellow foam. m.p. 195–196 °C; *R_f* 0.50 (CH₂Cl₂/MeOH 9:1); [α]^{18.9}_D -28.9 (*c* 1.53, MeOH); IR (ATR) ν_{\max} 3297, 2918, 1692, 1650, 1533, 1450, 1318, 1229 cm⁻¹; ¹H NMR (CHCl₃, 500 MHz) δ 8.09 (1H, d, *J* = 7.2 Hz, NH-5), 7.89 (2H, d, *J* = 7.4 Hz, 2H-FmocAr), 7.74 (1H, d, *J* = 7.4 Hz, 1H-FmocAr), 7.72 (1H, d, *J* = 7.4 Hz, 1H-FmocAr), 7.50 (1H, d, *J* = 7.5 Hz, NH-1), 7.41 (2H, t, *J* = 7.4 Hz, H-FmocAr), 7.33 (2H, td, *J* = 7.4, 0.9 Hz, 2H-FmocAr), 4.27–4.15 (4H, m, CO₂CH₂CH, CO₂CH₂CH, H-6), 4.08 (1H, d, *J* = 7.5, 7.2 Hz, H-2), 1.27 (3H, d, *J* = 7.3 Hz, H₃-7), 1.22 (3H, d, *J* = 7.2 Hz, H₃-3); ¹³C NMR (CDCl₃, 125 MHz) δ 174.2 (C-8), 172.2 (C-4), 155.6 (CO₂CH₂CH), 143.9 (C-FmocAr), 143.8 (C-FmocAr), 140.7 (2C-FmocAr), 127.6 (2C-FmocAr), 127.1 (2C-FmocAr), 125.3 (2C-FmocAr), 120.1 (2C-FmocAr), 65.6 (CO₂CH₂CH), 49.7 (C-2), 47.5 (C-6), 46.7 (CO₂CH₂CH), 18.2 (C-3), 17.3 (C-7); (+)-HRESIMS [M+Na]⁺ 405.1424 (calcd. for C₂₁H₂₂NaN₂O₅, 405.1421).

4.1.16. Fmoc-[Ala¹,Ala²]-halocyclamine A (**24 HF8-81**)

Fmoc-L-Ala-L-Ala **22 HF8-58** (0.176 g, 0.461 mmol), EDC.HCl (0.097 g, 0.507 mmol) and HOBt (0.093 g, 0.691 mmol) was dissolved in DMF (1.5 mL) and the mixture was stirred for 1 h at r.t. under N₂. A solution of **4 HF3.1** (0.135 g, 0.461 mmol) in DMF (1.5 mL) was added to the mixture followed by DIPEA (0.40 mL, 2.30 mmol). The solution was stirred at r.t. under N₂ for 7 h. The solution was diluted with EtOAc (10 mL) and washed with water (5 mL). The organic layer was dried (MgSO₄), filtered and the solvent removed *in vacuo*. The crude product was purified by silica gel flash column chromatography (eluting with *n*-hexane/EtOAc 8:2 to *n*-hexane/EtOAc/MeOH 5:4.5:0.5) to afford **24 HF8-81** (0.10 g, 33%) as a yellow oil. *R_f* 0.34 (EtOAc); [α]^{21.1}_D -6.7 (*c* 0.36, MeOH); IR (ATR) ν_{\max} 3019, 2978, 1595, 1488, 1451, 754 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.43 (1H, s, NH-17), 9.13 (1H, d, *J* = 10.0 Hz, NH-12), 8.14 (1H, t, *J* = 5.7 Hz, NH-9), 8.03 (1H, d, *J* = 7.4 Hz, NH-5), 7.88 (2H, d, *J* = 7.3 Hz, 2H-FmocAr), 7.73–7.40 (3H, m, 2H-FmocAr and H-16), 7.58–7.54 (2H, m, H-18 and H-21), 7.52 (1H, d, *J* = 7.7 Hz, NH-1), 7.41 (2H, t, *J* = 7.3 Hz, 2H-FmocAr), 7.32 (2H, t, *J* = 7.3 Hz, 2H-FmocAr), 7.16 (1H, dd, *J* = 8.4, 1.7 Hz, H-20), 6.66 (1H, dd, *J* = 10.0, 9.7 Hz, H-13), 5.91 (1H, d, *J* = 9.7 Hz, H-14), 4.35–4.31 (1H, m, H-6), 4.27–4.18 (3H, m, CO₂CH₂CH and CO₂CH₂CH), 4.10–4.05 (1H, m, H-2), 3.94 (2H, d, *J* = 5.7 Hz, H₂-10), 1.23 (3H, d, *J* = 6.7 Hz, H₃-7), 1.21 (3H, d, *J* = 6.9 Hz, H₃-3); ¹³C NMR (DMSO-*d*₆, 75 MHz) δ 172.7 (C-8), 172.2 (C-4), 167.5 (C-11), 155.7 (CO₂CH₂CH), 143.9 (C-FmocAr), 143.8 (C-FmocAr), 140.7 (2C-

FmocAr), 136.4 (C-17a), 127.6 (2C-FmocAr), 127.1 (2C-FmocAr), 125.7 (C-21a), 125.3 (2C-FmocAr), 124.9 (C-16), 121.9 (C-20), 120.1 (2C-FmocAr and C-21), 118.7 (C-13), 114.3 (C-19), 114.0 (C-18), 109.8 (C-15), 102.2 (C-14), 65.6 (CO₂CH₂CH), 50.0 (C-2), 48.1 (C-6), 46.6 (CO₂CH₂CH), 42.3 (C-10), 18.2 (C-3 or C-7), 18.1 (C-3 or C-7); (+)-HRESIMS [M+Na]⁺ 680.1474 (calcd. for C₃₃H₃₂⁷⁹BrNaN₅O₅, 680.1479).

4.1.17. [Ala¹,Ala²]-halocytamine A (**20 HF8-100**)

To **24 HF8-81** (19.0 mg, 0.0289 mmol) was added piperidine (20% in DMF, 1 mL) and flushed with nitrogen. The solution was stirred at r.t. for 20 min before EtOAc (20 mL) was added and the mixture was washed with water (10 mL). The aqueous layer was further washed with EtOAc (3 × 10 mL) and the organic layers were combined and dried *in vacuo*. Purification by silica gel column chromatography (eluting with EtOAc to CH₂Cl₂/MeOH 8:2), afforded **20 HF8-100** (7.54 mg, 60%) as a yellow oil. *R*_f 0.20 (CH₂Cl₂/MeOH 8:2); [α]^{19.4}_D +1.6 (*c* 0.26, MeOH); IR (ATR) *v*_{max} 3393, 2258, 1655, 1048, 1024 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.49 (1H, br s, NH-17), 9.11 (1H, d, *J* = 10.1 Hz, NH-12), 8.26 (1H, d, *J* = 5.7 Hz, NH-9), 8.08 (1H, br s, NH-5), 7.70 (1H, s, H-16), 7.58 (1H, d, *J* = 1.8 Hz, H-18), 7.56 (1H, d, *J* = 8.4 Hz, H-21), 7.16 (1H, dd, *J* = 8.4, 1.8 Hz, H-20), 6.66 (1H, dd, *J* = 10.1, 9.7 Hz, H-13), 5.91 (1H, d, *J* = 9.7 Hz, H-14), 4.33 (1H, d, *J* = 7.2 Hz, H-6), 3.93 (2H, d, *J* = 5.7 Hz, H₂-10), 3.29 (1H, obs, H-2), 1.23 (3H, d, *J* = 7.2 Hz, H₃-3), 1.13 (3H, d, *J* = 6.9 Hz, H₃-3); ¹³C NMR (DMSO-*d*₆, 75 MHz) δ 175.1 (C-4), 172.9 (C-8), 167.5 (C-11), 136.4 (C-17a), 125.6 (C-21a), 124.9 (C-16), 121.9 (C-20), 120.1 (C-21), 118.7 (C-13), 114.3 (C-19), 114.0 (C-18), 109.7 (C-15), 102.2 (C-14), 50.1 (C-2), 47.7 (C-6), 42.3 (C-10), 21.1 (C-3), 18.5 (C-7); (+)-HRESIMS [M+H]⁺ 436.0970 (calcd. for C₁₈H₂₃⁷⁹BrN₅O₃, 436.0979).

4.1.18. Fmoc-D-Ala-D-Ala-OH (**23 HF8-86**)

The synthesis of **23 HF8-86** used Fmoc-D-Ala-OH and the same procedure as described for the synthesis of Fmoc-L-Ala-L-Ala-OH (**22 HF8-58**), to give the product (0.45 g, 79%) as a white solid. m.p. 196–197 °C; *R*_f 0.23 (CH₂Cl₂/MeOH 9:1); [α]^{18.2}_D +19.7 (*c* 0.35, MeOH); IR (ATR) *v*_{max} 3293, 2990, 1688, 1653, 1534, 1450, 1319, 1262 cm⁻¹; ¹H NMR (CHCl₃, 400 MHz) δ 12.52 (1H, br s, OH), 8.13 (1H, d, *J* = 7.2 Hz, NH-5), 7.89 (2H, d, *J* = 7.4 Hz, 2H-FmocAr), 7.73 (1H, d, *J* = 7.4 Hz, 1H-FmocAr), 7.72 (1H, d, *J* = 7.4 Hz, 1H-FmocAr), 7.50 (1H, d, *J* = 7.5 Hz, NH-1), 7.41 (2H, t, *J* = 7.4 Hz, H-FmocAr), 7.32 (2H, td, *J* = 7.4, 0.9 Hz, 2H-FmocAr), 4.26–4.17 (4H, m, CO₂CH₂CH, CO₂CH₂CH, H-6), 4.08 (1H, d, *J* = 7.5, 7.2 Hz, H-2), 1.27 (3H, d, *J* = 7.3 Hz, H₃-7), 1.22 (3H, d, *J* = 7.2 Hz, H₃-3); ¹³C NMR (CDCl₃, 100 MHz) δ 174.0 (C-8), 172.3 (C-4), 155.6 (CO₂CH₂CH), 143.9 (C-FmocAr), 143.8 (C-FmocAr), 140.7 (2C-FmocAr), 127.6 (2C-FmocAr), 127.1 (2C-FmocAr), 125.3 (2C-FmocAr), 120.1 (2C-FmocAr), 65.6 (CO₂CH₂CH), 49.7 (C-2), 47.4 (C-6), 46.6

(CO₂CH₂CH), 18.2 (C-3), 17.2 (C-7); (+)-HRESIMS [M+Na]⁺ 405.1423 (calcd. for C₂₁H₂₂NaN₂O₅, 405.1421).

4.1.19. Fmoc-[D-Ala¹,D-Ala²]-halocytamine A (**25 HF8-95**)

Fmoc-D-Ala-D-Ala **23 HF8-86** (0.102 g, 0.266 mmol), EDC.HCl (0.056 g, 0.293 mmol) and HOBT (0.054 g, 0.399 mmol) were dissolved in DMF (1.5 mL) and stirred at r.t. for 1 h under nitrogen. A solution of **4 HF3.1** (0.078 g, 0.266 mmol) in DMF (1.5 mL) was then added followed by DIPEA (0.23 mL, 1.33 mmol). The solution was further stirred at r.t. for 7 h. EtOAc (10 mL) was added to the mixture and washed with water (5 mL). The organic layer was dried (MgSO₄), filtered and the solvent removed in vacuo. The crude product was purified by silica gel flash column chromatography (eluting with *n*-hexane/EtOAc 8:2 to *n*-hexane/EtOAc/MeOH 5:4.5:0.5) to afford **25 HF8-95** (60.0 mg, 34%) as a yellow oil. *R*_f 0.21 (*n*-hexane/EtOAc/MeOH 5:4.5:0.5); [α]^{21.5}_D +5.6 (*c* 0.32, MeOH); IR (ATR) *v*_{max} 3367, 2974, 1656, 1494, 1447, 1231, 1130 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.43 (1H, s, NH-17), 9.13 (1H, d, *J* = 9.9 Hz, NH-12), 8.14 (1H, d, *J* = 5.8 Hz, NH-9), 8.03 (1H, d, *J* = 7.7 Hz, NH-5), 7.89 (2H, d, *J* = 7.2 Hz, 2H-FmocAr), 7.74–7.70 (3H, m, 2H-FmocAr and H-16), 7.58–7.54 (2H, m, H-18 and H-21), 7.52 (1H, d, *J* = 7.1 Hz, NH-1), 7.41 (2H, t, *J* = 7.2 Hz, 2H-FmocAr), 7.33 (2H, t, *J* = 7.2 Hz, 2H-FmocAr), 7.16 (1H, dd, *J* = 8.5, 1.8 Hz, H-20), 6.67 (1H, d, *J* = 9.9, 9.7 Hz, H-13), 5.91 (1H, d, *J* = 9.7 Hz, H-14), 4.35–4.31 (1H, m, H-6), 4.27–4.21 (3H, m, CO₂CH₂CH and CO₂CH₂CH), 4.10–4.05 (1H, m, H-2), 3.94 (2H, d, *J* = 5.8 Hz, H₂-10), 1.23 (3H, d, *J* = 6.9 Hz, H₃-7), 1.21 (3H, d, *J* = 7.2 Hz, H₃-3); ¹³C NMR (DMSO-*d*₆, 75 MHz) δ 172.7 (C-8), 172.2 (C-4), 167.4 (C-11), 155.7 (CO₂CH₂CH), 143.9 (C-FmocAr), 143.8 (C-FmocAr), 140.7 (2C-FmocAr), 136.4 (C-17a), 127.6 (2C-FmocAr), 127.1 (2C-FmocAr), 125.7 (C-21a), 125.3 (2C-FmocAr), 124.8 (C-16), 121.9 (C-20), 120.1 (2C-FmocAr and C-21), 118.7 (C-13), 114.3 (C-19), 114.0 (C-18), 109.7 (C-15), 102.1 (C-14), 65.6 (CO₂CH₂CH), 49.9 (C-2), 48.0 (C-6), 46.6 (CO₂CH₂CH), 42.3 (C-10), 18.2 (C-3 or C-C-7), 18.1 (C-3 or C-C-7); (+)-HRESIMS [M+Na]⁺ 680.1464 (calcd. for C₃₃H₃₂⁷⁹BrNaN₅O₅, 680.1479).

4.1.20. [D-Ala¹,D-Ala²]-halocytamine A (**21 HF8-136**)

Piperidine (20% in DMF, 1 mL) was added to **25 HF8-95** (34.2 mg, 0.52 mmol) and stirred at r.t. under N₂ for 20 min. EtOAc (20 mL) was added and the mixture was washed with water (10 mL). The aqueous layer was further washed with EtOAc (3 × 10 mL) and the organic layers were combined and dried *in vacuo*. Purification by silica gel column chromatography (eluting with EtOAc to CH₂Cl₂/MeOH 8:2), afforded **21 HF8-136** (15.7 mg, 69%) as a clear film. *R*_f 0.22 (CH₂Cl₂/MeOH 8:2); [α]^{21.4}_D -0.5 (*c* 1.59, CH₂Cl₂); IR (ATR) *v*_{max} 3274, 2921, 2854, 1646, 1532, 1449, 1398, 1235, 1054 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz) δ 7.55 (1H, d, *J* = 1.5 Hz, H-18), 7.51 (1H, d, *J* = 0.8 Hz,

H-16), 7.47 (1H, d, $J = 8.5$ Hz, H-21), 7.18 (1H, dd, $J = 8.5, 1.5$ Hz, H-20), 6.76 (1H, d, $J = 9.2$ Hz, H-13), 6.00 (1H, dd, $J = 9.2, 0.76$ Hz, H-14), 4.36 (1H, d, $J = 7.1$ Hz, H-6), 3.97 (2H, s, H₂-10), 3.48 (1H, d, $J = 6.9$ Hz, H-2), 1.33 (3H, d, $J = 7.1$ Hz, H₃-7), 1.26 (3H, d, $J = 6.9$ Hz, H₃-3); ¹³C NMR (CD₃OD, 75 MHz) δ 177.0 (C-3), 175.7 (C-8), 169.4 (C-11), 138.4 (C-17a), 127.2 (C-21a), 125.5 (C-16), 123.6 (C-20), 121.0 (C-21), 120.0 (C-13), 116.4 (C-19), 115.3 (C-18), 111.4 (C-15), 105.5 (C-14), 51.2 (C2), 50.4 (C-6), 43.9 (C-10), 20.6 (C-3), 17.9 (C-7); (+)-HRESIMS [M+Na]⁺ 458.0800 (calcd. for C₁₈H₂₂⁷⁹BrNaN₅O₃, 458.0798).

4.2. Antibacterial assays[ref10]

The antibacterial activity of the compounds was studied by determination of minimum inhibitory concentrations (MICs) using the standard broth dilution method in accordance with the NCCLS guidelines M7-A2. Briefly, the MICs were determined with an inoculum of 10⁵ CFU in 200 μ L of MH broth containing twofold serial dilutions of each drug. The MIC was defined as the lowest concentration of drug that completely inhibited visible growth after incubation for 18 h at 37 °C. To determine all MICs, the measurements were independently repeated at least three times. Minimum inhibitory concentration of positive control: colistin [*P. aeruginosa* (1 μ M), *E. coli* (2 μ M)], streptomycin [*P. aeruginosa* (21.5 μ M), *E. coli* (21.5 μ M), *S. aureus* (21.5 μ M), and *E. faecalis* (21.5 μ M)] and chloramphenicol [*S. aureus* (1.5–3 μ M), and *E. faecalis* (1.5–3 μ M)].

4.3. In vitro cytotoxicity assay[ref11]

Assays were performed in 96-well microtiter plates, each well containing 100 μ L of RPMI 1640 medium supplemented with 1% L-glutamine (200 mM) and 10% fetal bovine serum, and 4 \times 10⁴ L6 cells (a primary cell line derived from rat skeletal myoblasts). Serial drug dilutions of seven 3-fold dilution steps covering a range from 90 to 0.123 μ g/mL were prepared. After 72 h of incubation, the plates were inspected under an inverted microscope to assure growth of the controls and sterile conditions. Alamar Blue solution (10 μ L) was then added to each well and the plates incubated for another 2 h. Then the plates were read with a Spectramax Gemini XS microplate fluorometer using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data were analysed using the microplate reader software Softmax Pro. Podophyllotoxin was the reference drug used.

Acknowledgments

The authors thank Dr. M. Schmitz and Mr T. Chen (University of Auckland) for assistance with NMR and MS data acquisition, and Dr M. Kaiser (Swiss Tropical Public Health Institute, Basel Switzerland) for cytotoxicity data. We gratefully acknowledge funding from the University of Auckland.

Supplementary data

Copies of ^1H and ^{13}C NMR spectra for all products. Supplementary data associated with this article can be found in the online version, at <http://dx.doi.org/10.1016/>. These data include MOL files and InChiKeys of the most important compounds described in this article.

References

- Ref1 Tunichrome review Taylor SW, Kammerer B, Bayer, E. *Chem. Rev.*, 1997; 97:333.
- Ref2 Sugumaran M, Robinson WE. *Mar. Drugs*, 2010; 8:2906.
- Ref3 Smith MJ, Kim D, Horenstein B, Nakanishi K, Kustin K. *Acc. Chem. Res.*, 1991; 24:117.
- Ref4 tunic formation/cross-linking Cai M, Sugumaran M, Robinson WE. *Comp. Biochem. Physiol. Part B: Biochem Mol. Biol.*, 2008; 151:110.
- Ref5 ion sequestration Paik Y-S. *Arch. Pharm. Res.*, 1992; 15:269.
- Ref6 Sp-1 synth Pullar MA, Barker D, Copp BR. *Tetrahedron Lett.*, 2015; 56:5604.
- Ref7 Halo A synth Fong HKH, Brunel JM, Longeon A, Bourguet-Kondracki M.-L, Barker D, Copp BR. *Org. Biomol. Chem.*, 2017; 15:6194.
- Ref8 Unsworth 2013 Unsworth WP, Cuthbertson JD, Taylor RJK. *Org Lett.* 2013; 15:3306.
- Ref9 Sever 2001 Sever MJ, Wilker JJ. *Tetrahedron* 2001; 57:6139.
- Ref10 Pieri C, Borselli D, Di Giorgio C, De Méo M, Bolla J-M, Vidal N, Combes S, Brunel JM. *J Med Chem.* 2014; 57:4263–4272.
- Ref11 Orhan I, Şener B, Kaiser M, Brun R, Tasdemir D. *Mar Drugs*. 2010;8:47–58.